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Abstract
Phytoestrogens are polyphenolic secondary plant metabolites that have structural and functional similarities to 17-oestradiol. They can interact with oestrogen receptors and disrupt the sex-hormone pathway. These compounds have been associated with a protective effect against hormone related cancers such as breast and prostate cancer, however, epidemiological evidence so far has been inconclusive. Most foods in the UK only contain small amounts of phytoestrogens (median content: 21 µg/100 g) and the highest content is found in soya and soya containing foods. The highest phytoestrogen content in commonly consumed foods is found in breads (average content 450 µg/100 g) which are also the main source of isoflavones in the UK diet. No significant associations between phytoestrogen intake and breast cancer risk in a nested case-control study in EPIC Norfolk were found. Conversely, colorectal cancer risk was inversely associated with enterolignan intake (OR 0.44; 95% CI 0.19 – 1.00) in women but not in men. Prostate cancer risk was positively associated with enterolignans intake, however this association became non-significant when adjusting for dairy intake, suggesting that enterolignans can act as a surrogate marker for dairy or calcium intake. 
1	Introduction
Phytoestrogens are a group of non-steroidal polyphenolic plant metabolites that induce biological responses and can mimic or modulate the action of endogenous oestrogens, often by binding to oestrogen receptors [1]. In animals, adverse effects of phytoestrogen-rich fodder such as infertility and hyper-oestrogenisation have first been described in the 1940s as “clover-disease” in sheep grazing on clover-rich pastures [2]. Subsequently, the adverse effects of oestrogenic plant compounds have also been described in cattle  ADDIN EN.CITE [3-5], Guinea pigs [3, 6], rabbits [7], mice [8] and cheetahs [9]. Despite these adverse effects in animals, similar effects have not been observed in humans on a phytoestrogen rich diet [10]. 
The bioactivity of phytoestrogens is based on their structural similarity with 17–oestradiol  ADDIN EN.CITE [11-14] and their ability to bind to oestrogen receptors [15]. An aromatic ring and a hydroxyl-group are important features for a compound to bind to the receptor [16] and the structure of phytoestrogens with a p-hydroxy-substituted aromatic ring, 1.2 nm (12 Å) away from a second planar hydroxyl group, resembles the structure of oestradiol [17]. However, whereas oestradiol has a similar affinity for the oestrogen  and  receptor (ER and ER), there are marked differences for phytoestrogens. For example, the isoflavone genistein exhibits an up to 30-fold greater affinity for ER [18] and coumarins were shown to have a five-times higher relative binding affinity to ER [19]. Therefore, phytoestrogens may cause some of their clinical effects by selectively triggering ER mediated responses [18]. Compared with oestradiol, phytoestrogens have only a weak oestrogenic activity (10−2 to 10−3 compared with 17-oestradiol) but can compete with oestradiol at the receptor complex; however, they fail to stimulate a full oestrogenic response  ADDIN EN.CITE [20-25]. Apart from their effect on oestrogen receptors, phytoestrogens can also act as inhibitors of enzymes such as tyrosine kinase [26] and DNA toposiomerase  ADDIN EN.CITE [27]. It is however mainly their anti-oestrogenic activity which raises the possibility that they are protective in hormone-related diseases [28], in particular breast, colorectal or prostate cancer. Epidemiological studies conducted so far however have failed to show such an effect conclusively, in particular in populations with low habitual phytoestrogen consumption such as in Europe or the US. A meta-analysis of eight studies conducted in high soya-consuming Asians showed a protective effect of soya isoflavones against breast cancer, studies conducted in Europe [29]  ADDIN EN.CITE [30, 31] or the US [32] failed to find a significant effect. Likewise, of eight studies included in a meta-analysis to investigate associations between isoflavone intake and the risk for prostate cancer only those with the highest intake showed a significant (inverse) association [33].
2	Phytoestrogen consumption
The main sources of dietary phytoestrogens are fruits and vegetables, but they are also present in dairy products  ADDIN EN.CITE [34, 35] and in other foods of animal origin [36]. The principal classes of phytoestrogens are isoflavones (found mainly in legumes, chickpeas and soybean), prenylated flavonoids (present in hops), coumestans (found in young sprouting legumes like clover or alfalfa sprouts) and lignans (found in cereals, linseed and other fruits and vegetables) (Figure 1). In plants, phytoestrogens occur predominantly as glucosides which – upon consumption –  are hydrolysed by intestinal glucosidases to release aglycones [37]. These aglycones can then be further metabolised by the intestinal microflora; isoflavones to metabolites like equol and O‑desmethylangolensin,  ADDIN EN.CITE [34, 38]; lignans to enterolactone and enterodiol [39]. 
Phytoestrogen exposure can be determined using two different methods: either directly by measuring diet or indirectly by using biomarkers in plasma or urine  ADDIN EN.CITE [40]. Biomarkers are considered to be more reliable due to limitations in dietary assessment [41], but their application is often not feasible, in particular in larger studies or to assess exposure in the general population. Furthermore, the measurement of urinary or serum biomarker is often affected by inter-individual differences in metabolism as most analytical methods used for biomarker measurement only determine the most common metabolites (Figure 2). For this reason, accurate information on the phytoestrogen content of foods commonly consumed is crucial and several studies have been conducted so far (Table 1). 
2.1	Phytoestrogen content of UK food
We have recently developed the most comprehensive database of phytoestrogen content in UK food  ADDIN EN.CITE [36, 42-44], covering more than 500 items. The majority of foods consumed in the UK has a phytoestrogen content of less than 100 µg per 100 g wet weight, indeed the median content is 21 µg/100 g. The highest phytoestrogen content was found in soya and soya-containing foods, such as for example soya flour (125 mg/100 g), soya infant formula (19 mg/100 g), soya beans (18 mg/100 g) or soya milk (9 mg/100 g). The highest amount of phytoestrogens in non-soya containing foods was found in linseeds (19 mg/100 g). Lignans were the main type of phytoestrogens found in most foods, with the exception of foods from Fabaceae which contained mainly isoflavones, in particular daidzein, genistein and glycitein. High levels of biochanin A (400 µg/100 g) were only found in chick-peas and chick-pea based foods.
Despite knowledge of the presence of phytoestrogens in foods of animal origin for some time – in particular in milk  ADDIN EN.CITE [34-36] – very little data about the phytoestrogen content are available. We have conducted the first comprehensive analysis and found phytoestrogens in milk and dairy products, eggs, meat, fish and seafood [36], although the amount in some foods, in particular fish and seafood (2–9 µg/100 g), was very low. Whereas in meat, fish and seafood virtually all phytoestrogens are directly plant derived, a major proportion of the phytoestrogens found in eggs and dairy products were derived from gastro-intestinal metabolism of plant precursors. The phytoestrogen content in milk and other dairy products depends on a variety of factors such as fodder and season and vary between different countries, for example: Australia (5–29 µg/100 ml equol) [45], France (1–29 µg/100 ml equol, 1–9 µg/100 ml enterolactone) [46], Finland (6 µg/100 ml) [47] and the United Kingdom (1–8 µg/100 ml equol, 3–9 µg/100 ml enterolactone) [36]. 
The phytoestrogen content in eggs was lower than in milk products and most phytoestrogens (mainly isoflavones) were found in the yolk. In contrast to milk-based products, the amount of equol was higher than the amount of enterolignans present. Although the isoflavones content was highest in eggs from hens kept in barns, there was no statistically significant difference between different types of chicken husbandry.
The phytoestrogen content of some foods commonly consumed in the UK is shown in table 2. Most foods contain only small amounts and the main type of phytoestrogens are lignans. The highest amount of phytoestrogens in commonly consumed foods in the UK is found in bread where up to 1 mg/100 g were found in non-speciality breads (mean content 450 µg/100 g), although the phytoestrogen content of flour is only 20–40 µg/100 g. The main type of phytoestrogens in bread are isoflavones and they are derived from soya which is added to the dough as part of the Chorleywood Bread Process (CBP) [48] to help improve the bread quality; for this reason, bread is one of the main sources of phytoestrogens in the UK diet [49]. In countries where bread is prepared using different processes, the phytoestrogen content is considerably lower, for example 190 µg/100 g for commercial white bread in the US [50]. 
3	Phytoestrogens and cancer risk in EPIC Norfolk
The updated food composition database allowed a more accurate exploration of associations between dietary phytoestrogens and the risk for breast, colorectal and prostate cancer in a nested case-control study in EPIC Norfolk [31]. Between 1993 and 2006, 244 cases of breast cancer, 221 cases of colorectal cancer, and 204 cases of prostate cancer were diagnosed in the cohort, with a mean follow-up length of approximately nine years. Participants (11,607 men and 14,032 women; 45-75 years of age at recruitment) were recruited between 1993 and 1997 and details of health and lifestyle, anthropometric measurements and dietary data (7-day-diary and food-frequency questionnaires) were recorded at baseline [51].
3.1	Breast cancer
Mean intake of phytoestrogens was similar between controls and cases of breast cancer, although lignan intake, in particular secoisolariciresinol, was marginally higher among breast cancer cases (229±102 µg/g vs 215±92 µg/g; cases vs controls). For nearly all compounds under study, breast cancer risk was not associated with phytoestrogen intake. In the age-adjusted logistic regression models, lignan intake was associated with increased breast cancer risk (OR for doubling of intake 1.29; 95% CI 1.00 – 1.66); however, this association was attenuated in the multivariate analyses (OR 1.17; 95% CI 0.88 – 1.57) [31]. This confirms previous results using urine and serum biomarkers [52] where no significant associations were detected.
3.2	Colorectal cancer
Colorectal cancer cases and controls did not differ significantly in terms of age, height, weight, or the intake of phytoestrogens or any of the dietary factors under study. There was no association between phytoestrogen intake and colorectal cancer risk in men, neither in the age-adjusted nor in the multivariable model. However, in women there was an inverse association between colorectal cancer and intake of enterolactone (OR 0.44, 95% CI 0.21 – 0.95) and total enterolignans (OR 0.44, 95% CI 0.19 – 1.00) in the multivariable, but not in the age adjusted model. In the multivariable model, there was also a marginally significant positive association between secoisolariciresinol intake and colorectal cancer risk (OR 1.60, 95% CI 0.96 – 2.69) [31]. In contrast to this, these differences between men and women have not been found in a recent study using urinary and serum biomarker where no associations were found [53].
3.3	Prostate cancer 
Prostate cancer cases were taller and heavier, and reported higher average intake of energy and fat than controls; likewise, cases had a higher mean intake of enterolactone, equol, total enterolignans, total dairy, and calcium (Table 3). However, prostate cancer cases and controls did not differ in mean intake of lycopene, zinc, the distribution of physical activity levels, social class, or family history of prostate cancer.
In the age adjusted analysis, prostate cancer risk was positively associated to intake of equol, enterolactone and total enterolignans (OR 1.41; 95% CI 1.12 – 1.76), but these associations became marginal in the multivariable model (OR 1.27; 95% CI 0.97 – 1.66). The main sources of these compounds are milk and dairy products and there is a strong and significant correlation between the intake of total enterolignans and dietary calcium (r=0.85; p<0.0001) as marker of dairy intake and total dairy consumption (r=0.78; p<0.0001). In contrast, the correlation for all other phytoestrogens were less than 0.2 [31]. When dietary dairy was included into the multivariable model, the previously significant associations for equol, enterolactone, and total enterolignans became non-significant (OR 1.19; 95% CI 0.77 – 1.82); similar results were obtained when using dietary calcium as surrogate marker for dairy intake. Positive associations between dairy intake and prostate cancer risk have been reported previously [54] and these results confirm this. The data available do not allow to identify whether enterolignans are simply a surrogate marker for the intake of dairy products or whether they affect the risk for prostate cancer independently [31]. The lack of association with lignan intake however does suggest that these compounds act as a surrogate marker for dairy or calcium intake. Dietary lignans are metabolised to enterolignans by the colonic microflora [39] and enterolignans and most lignans result in the same bioactive form following absorption. If enterolignans were directly associated with prostate cancer, a similar association could be expected for dietary lignans, possibly stronger because lignan intake (297 µg/d in controls) is much higher than enterolignans intake (18 µg/d). This is also confirmed by results from a previous study using urinary and serum biomarkers where no significant associations between enterolignans and prostate cancer were detected [53]. 
4	Discussion
The recently developed food-composition database for foods commonly consumed in the UK allowed a more accurate estimation of phytoestrogen exposure in the EPIC-Norfolk population. Furthermore, this database provided for the first time comprehensive information about the phytoestrogen content of foods of animal orgin such as meat, dairy and seafood and phytoestrogens that are formed as result of the gut flora metabolism such as enterolactone and equol. Whereas no statistically significant associations between directly plant-derived phytoestrogens and breast, colorectal and prostate cancer were found, there were significant association for enterolactone and equol; they were associated with a reduction in risk in colorectal cancer among women in EPIC-Norfolk and an increased risk for prostate cancer. However, the association for prostate cancer became non significant when adjusting for dairy or calcium intake, suggesting that these compounds can act as a surrogate marker for intake of dairy products or calcium.
The lack of association between most phytoestrogens and breast, colorectal and prostate cancer is consistent with earlier reports from epidemiological studies with a comparable phytoestrogen intake. However, only few studies take inter-individual differences in the metabolism of these compounds into account. Phytoestrogens undergo extensive metabolism, not only by the gastro-intestinal microflora but also by the intestinal wall and the liver. The extend of metabolism is highly variable among individuals [55] and this is likely to have important implications on their bioactivity. Furthermore, gene-nutrient interactions between phytoestrogens and estrogen receptor polymorphisms (ESR1 and NR1I2) [56, 57], polymorphisms in the gene for the sex-hormone binding globulin (SHBG) [58] and probably polymorphisms in the gene encoding aromatase (CYP19) [59] also affect their bioactivity. These differences in metabolism and gene-nutrient interaction are likely to attenuate possible biological effects of these compounds in epidemiological studies and could be an explanation for the lack of association found.
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Table 1:	Food databases used to assess dietary intake of phytoestrogens. 
				Foods analysed	Compounds analysed
Study	Foods analysed	Method	Internal Standard	Soy & Soy products	Nuts, Seeds & Oils	Fruits & Vegetables	Cereals & Breads	Meat, Fish, Eggs & Seafood	Dairy products	Beverages	Other	Isoflavones	Lignans	Coumestans	Enterolignans & Equol
Horn-Ross et al., [60]	42	LC/MS/MS (APCI)	4-methylumbelliferone	7	1	16	4	2	1	2	9	4	2	1	
Liggins et al. [61]	78	GC/MS	Standard Addition	3			75					2			
Liggins et al. [62]	80	GC/MS	Standard Addition		13	67						2			
Liggins et al. [63]	114	GC/MS	Standard Addition	2		112						2			
Mazur et al. [64]	48	GC/MS	Deuterated	4		44						4	2	1	
Mazur [65]	65	GC/MS	Deuterated	1	8	40	6			10		4	2	1	
Milder et al. [66]	76	LC/MS/MS	Deuterated	1	11	52	9				3		4		
Penalvo et al. [67]	86	GC/MS	13C-labelled	6		73	4	1	2				6		
Penalvo et al. [68]	17	GC/MS	13C-labelled			10	7								
Smeds et al. [69]	22	LC/MS/MS	Deuterated		6		16						24		
Thompson et al. [70]	125	GC/MS	5a-androstane,
17b-estradiol	14	12	56	14	5	2	10	12	4	4	1	
Valsta et al.  ADDIN EN.CITE [71]	180	GC/MS†	Deuterated	160 foods for isoflavones, 180 foods for lignans
Kuhnle et al.  ADDIN EN.CITE [42]	40	LC/MS/MS	13C-labelled		3					37		4	3	1	
Kuhnle et al. [36]	115	LC/MS/MS	13C-labelled	8				30	73		4	4	3	1	3
Kuhnle et al. [44]	102	LC/MS/MS	13C-labelled				102					4	3	1	
Kuhnle et al. [43]	247	LC/MS/MS	13C-labelled	5		235					7	4	3	1	
Kuhnle et al.. (Summary)	504			13	3	235	102	30	73	37	11	16	12	4	


† compilation of results determined mainly by GC/MS with deuterated standards, but some foods were analysed by HPLC.





















Table 3:	Significant differences (t-test; p<0.05) between prostate cancer cases and controls in EPIC-Norfolk
	Cases (n = 204)	Controls (n=812)
	Mean ± SD	Mean ± SD
Height (cm)	172 ± 7	173 ± 6  
Weight (kg)	785 ± 11	80 ± 11  
Energy intake (kcal/d)	2216 ± 482 	2135 ± 511  
Fat intake (g/d)	85 ± 24.2	81 ± 25  
Total enterolignans (µg/d)    	20 ± 9	18 ± 9
Dairy products (g/d)	303 ± 168	266 ± 161
Calcium intake (mg/d)	936 ± 288	874 ± 284
 





Figure 2: 	Assessment of phytoestrogen exposure by biomarker. Dietary phytoestrogens (A) undergo extensive metabolism both by the gastro-intestinal microflora and upon uptake in the human body. However, most analytical methods for biomarker measurements only determine the most common metabolites (e.g. B) whereas other metabolites (C) remain undetected. Inter-individual difference in metabolism will therefore affect the apparent biomarker concentration and can therefore introduce larger variability and lead to underestimation of exposure.





